Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

PET/CT: Toshiba presents new large-bore system

Toshiba is bringing what is being called the industry’s largest-bore PET/CT to the upcoming Radiological Society of North America (RSNA) annual meeting next month in Chicago from Nov. 30-Dec. 5, according to an Oct. 27 announcement.

Thumbnail

Lilly to pay reduced punitive damages in bladder cancer trial

Eli Lilly and Company, makers of amyloid PET agent Amyvid, announced yesterday evening that the judge in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, has ruled to reduce punitive damages for defendants Takeda and Lilly from $6 billion and $3 billion, respectively, down to $27.6 million and $9.2 million.

Thumbnail

Hyperpolarized lung MRI portrays the perils of smoking

A relatively new MR technique that vastly improves imaging resolution is able to find the minute lung pathology associated with smoking habits—even before respiratory symptoms become a drag, according to a study published ahead of print Oct. 13 in Radiology.

Thumbnail

Navidea names Rick Gonzalez chief executive officer

Rick Gonzalez, former vice president of global operations for Spectrum Pharmaceuticals, is the new chief executive officer for Navidea Biopharmaceuticals, producers of Lymphoseek, the company announced recently.

Sofie saddles $1.5M SBIR grant for phase II PET probes

Sofie Biosciences, producers of PET imaging systems and agents, has been awarded a two-year $1.5 million phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute to further develop oncologic PET agents, the company recently announced.

NanoHybrids gets NIH grant for atherosclerotic plaque imaging

The National Institutes of Health (NIH) will be bankrolling a Small Business Innovation Research (SBIR) grant for Austin-based NanoHybrids to develop contrast agents for the detection of atherosclerotic plaques, the company announced today.

CMS overhauls doctor payment website

The Centers for Medicare & Medicaid Services has relaunched its Open Payment website. The general impression is that the new site is worlds easier to navigate than its original launch.

Thumbnail

AstroZeneca and University of Cambridge team up for more projects

Pharmaceutical developers AstraZeneca announced Oct. 16 that the company’s research and development division, MedImmune, will be collaborating with the University of Cambridge on four new projects.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.